Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for HLN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for HLN and 80,000+ other tickers.
See exactly how HLN's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HLN and 80,000+ other tickers.
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands…
UBS, the Swiss investment bank, says an early rise in flu incidence could lift 2027 earnings forecasts for Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods group, and Haleon, the consumer health group. The bank rates Reckitt 'buy' with a price target of 7,600p, implying 39% upside from its Monday closing price of 5,484p.
Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing
Nostalgia-fueled experience introduces Excedrin Rapid Relief, providing fast relief of tough pain that starts in as little as 15 minutes Key Takeaways: Excedrin is introducing My Little Headache, a nostalgic digital-pet experience inspired by the handheld toys of the late '90s and early 2000s, capitalizing on the renewed popularity of digital pets among nostalgia-seeking consumers The interactive experience turns headache disruption into a playful, hard-to-ignore virtual pet that escalates through alerts, animations, and reactions As the digital pet becomes increasingly demanding, My Little Headache reminds consumers that headaches do not wait, and neither should relief. With Excedrin Rapid Relief's patented Fast Release Technology starting to provide relief in as little as 15 minutes, the pet transforms alongside the experience, playfully bringing to life the feeling of leaving headache pain behind and getting back to yourself Singer and actor Jesse McCartney helps bridge nostalgia and contemporary culture, reconnecting with longtime fans while building relevance with a new generation WARREN, N.J.
Goldman Sachs handpicks European stocks with the highest conviction for outperformance, and four of October's top selections carry a benefit most growth-focused investors overlook entirely.
Unilever PLC (LSE:ULVR) is on JP Morgan's 'positive watch', and Haleon PLC (LSE:HLN, NYSE:HLN) on 'negative watch', ahead of third-quarter reporting by European consumer staples companies. The note adds Givaudan to positive watch alongside Unilever, Heineken N.V.